Elastin-like polypeptide delivery system renal targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current elastin-like polypeptides (ELPs) lack predictable in vivo behavior due to varying physical properties such as chain length and hydrodynamic radius, which affects their targeting efficiency and stability in therapeutic delivery to specific kidney regions.
Innovation Solution
Development of ELPs with specific molecular weights and repeat units, such as up to 95 or greater than 95 VPGXG repeats, allowing for targeted delivery to the renal cortex or medulla by controlling their transition temperature and hydrodynamic radius, thereby enhancing stability and biodistribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If ELP chain length and hydrodynamic radius are varied to improve targeting efficiency to different kidney regions, then biodistribution and targeting specificity are improved, but in vivo behavior predictability and stability deteriorate
Solution Approach 1:
The patent applies parameter changes by systematically varying the ELP chain length (number of VPGXG repeat units) and hydrodynamic radius to optimize targeting efficiency. By controlling these physical parameters, the patent achieves predictable in vivo behavior and stable biodistribution patterns, resolving the contradiction between targeting specificity and predictability through defined parameter ranges rather than arbitrary variations.
Solution Approach 2:
The patent employs local quality by designing ELPs with specific molecular weight ranges (e.g., 5-38 kDa for cortical targeting, 38-257 kDa for medullary targeting) that confer distinct biodistribution properties to different kidney regions. This localized optimization of physical properties enables region-specific targeting while maintaining overall system predictability and stability.
2Stability of the object's composition
If ELP molecular weight is increased to prolong half-life and enhance stability, then therapeutic delivery stability is improved, but renal clearance and biodistribution efficiency deteriorate
Solution Approach 1:
The patent resolves this contradiction through parameter changes by establishing optimal molecular weight ranges for different therapeutic objectives. By defining specific MW thresholds (e.g., up to 38 kDa for cortical delivery, 38-257 kDa for medullary delivery), the patent achieves both prolonged half-life/stability and maintained renal clearance efficiency, eliminating the need to choose between these opposing properties.
Solution Approach 2:
The patent applies dynamics by creating a dynamic relationship between ELP molecular weight and renal handling. The system transitions from filtration-dominant clearance at lower molecular weights to receptor-mediated uptake and prolonged circulation at higher molecular weights, enabling flexible optimization of both stability and clearance efficiency based on therapeutic needs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ELPs with controlled molecular weights demonstrate prolonged half-life and differential targeting of kidney regions, achieving higher accumulation in specific areas and improved therapeutic delivery profiles.
Implementation Method 1
Development of ELPs with specific molecular weights and repeat units, such as up to 95 or greater than 95 VPGXG repeats, allowing for targeted delivery to the renal cortex or medulla by controlling their transition temperature and hydrodynamic radius
Data Source
AI summary
A renal cortex targeting elastin-like polypeptide (ELP), a renal medulla and cortex targeting ELP, and a method of treating a renal disorder are provided. The renal cortex targeting ELP includes up to 95 repeat units having the sequence VPGXG (SEQ ID NO: 1), where X in each of the repeat units is any amino acid except proline. The renal medulla and cortex targeting ELP includes at least 95 repeat units of SEQ ID NO: 1, where X in each of the repeat units is any amino acid except proline. The method of treating a renal disorder includes administering an ELP and a therapeutic drug to a subject in need thereof, where the ELP includes up to 671 repeat units of SEQ ID NO: 1 and X in each of the repeat units is any amino acid except proline.